We conclude that multiplexing markers will provide optimal disease surveillance for patients treated for very high–risk neuroblastoma, as performed for patient P3 by combining TERT breakpoint and ALK p.R1275Q marker surveillance in ctDNA. The gene discussed is ALK; the disease is neuroblastoma.